8-K: Relmada Therapeutics Boosts Executive Pay, Updates Severance

Relmada Therapeutics, Inc. announced amended employment agreements for its executive officers, including salary increases and revised severance packages, effective January 1, 2026.

Summary

• Relmada Therapeutics, Inc. approved amended and restated employment agreements for its executive officers, effective January 1, 2026.
• CEO Sergio Traversa's annual base salary increased from $787,787 to $827,176. His target cash bonus is 50% of base salary.
• COO Paul Kelly's annual base salary increased from $499,800 to $524,790. His target cash bonus is 40% of base salary.
• CFO Maged Shenouda's annual base salary increased from $558,990 to $586,940. His target cash bonus is 40% of base salary.
• Chief Accounting and Compliance Officer Charles Ence's annual base salary increased from $548,990 to $576,440. His target cash bonus is 40% of base salary.
• Severance provisions for termination without cause or resignation for good reason (not related to Change in Control) include: CEO: 24 months of compensation (salary + target bonus) and 24 months of health benefits; COO, CACO: 12 months of compensation (salary + target bonus) and 12 months of health benefits; CFO: 12 months of compensation (salary + target bonus) and continued health benefits for the longer of 12 months or until eligible for Medicare (Part A or B) and 65 years of age.
• Severance provisions for termination without cause or resignation for good reason within 12 months of a Change in Control include: CEO: 30 months of compensation (salary + target bonus) and 30 months of health benefits; COO, CFO, CACO: 18 months of compensation (salary + target bonus) and 12 months of health benefits (CFO's health benefit term is longer as noted above).
• All outstanding equity and long-term incentive awards for executives become immediately vested and exercisable upon qualifying termination events.
• Agreements include non-solicitation clauses for 24 months post-employment and provisions for arbitration of disputes.

Sentiment

Score: 6

Explanation: The filing details routine executive compensation adjustments and updated employment agreements. While salary increases and enhanced severance packages represent increased costs, they are standard for executive retention and do not indicate any immediate positive or negative operational performance. The comprehensive nature of the agreements provides clarity on executive terms.

Positives

• Increased base salaries for all executive officers, potentially enhancing executive retention and motivation.
• Enhanced severance packages, particularly in Change in Control scenarios, provide financial security for executives.
• Immediate vesting of equity awards upon qualifying termination events aligns executive interests with shareholder value creation.

Negatives

• Increased compensation and severance commitments could lead to higher operational costs for the company.
• Generous severance packages, especially in Change in Control scenarios, may be viewed as a significant financial obligation for the company and its shareholders.

Risks

• Potential financial burden from substantial severance payments if executive employment is terminated, particularly following a Change in Control.
• Risk of disputes arising from employment terms, which would be subject to arbitration.
• The company's ability to cancel or change benefit plans at any time, subject to applicable law, could impact employee satisfaction.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the terms of executive compensation and potential future equity grants.

Management Comments

• "On behalf of Relmada Therapeutics, Inc: (the Company), I am pleased to offer you the position of Chief Accounting and Compliance Officer. Speaking for myself, as well as the other members of the Board of Directors, we are all impressed with your credentials and look forward to your future success in this position." (From Charles Ence's agreement, signed by Sergio Traversa, CEO).
• "Relmada Therapeutics, Inc. (the Company) desires to continue to employ you and to have the benefit of your skills and services." (From Sergio Traversa's agreement).

Industry Context

These executive compensation adjustments and updated employment agreements are a standard practice for publicly traded companies to retain key talent and align executive incentives with corporate performance and long-term strategic goals. The structure of base salary, performance bonuses, and equity grants, along with severance provisions, is typical for executive contracts in the biotechnology or pharmaceutical industry, aiming to attract and retain high-caliber leadership.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Any dispute or claim arising from employment (except confidentiality agreement enforcement) will be settled by arbitration in New York, New York, under American Arbitration Association rules.
• The company will pay arbitration fees, and the cost of the arbitrator will be equally divided.
• The company will pay the employee's legal fees if the employee substantially prevails in legal proceedings related to the agreement.

Stakeholder Impact

• Shareholders: Potential impact from increased executive compensation and severance liabilities, which could affect profitability and shareholder value if not justified by performance. However, clear executive contracts can also provide stability.
• Employees: The company reserves the right to cancel and/or change benefit plans, which could impact general employee benefits, though executives participate in standard plans.
• Executives: Directly impacted by increased salaries, performance bonus opportunities, enhanced severance protections, and immediate vesting of equity awards upon qualifying termination events.

Next Steps

• The Board will establish written individual and corporate performance objectives for the balance of 2020 (for CEO) and for each subsequent calendar year at least thirty (30) days before the start of the year.
• The Board will determine the amount of any performance bonus payable within sixty (60) days after the end of each calendar year.
• Executives may be awarded grants under the Company's 2021 Stock Option and Equity Incentive Plan, as amended, subject to Board approval.

Key Dates

Recommendation

The filing details routine, albeit increased, executive compensation and updated severance agreements. While these changes provide clarity and incentives for key management, they do not present new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment stance. Investors should continue to hold and monitor the company's core business developments and financial results.

Keywords

Relmada Therapeutics, Executive Compensation, Employment Agreement, CEO Salary, CFO Salary, COO Salary, Chief Accounting Officer, Severance Package, Change in Control, Corporate Governance, SEC Filing, RLMD